Abbott Laboratories vs Novo Nordisk
Abbott Laboratories (ABT), health care, and Novo Nordisk (NVO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Abbott Laboratories is worth $184.1B on the stock market and Novo Nordisk $179B: Abbott Laboratories is valued at 3% more. Abbott Laboratories trades at 39.7 times earnings and Novo Nordisk at 10.3; operating margins in their latest fiscal years were 18.2% and 41.3%. Over the past year Abbott Laboratories's share price has moved -17.3% and Novo Nordisk's -12.5%.
Key facts
- Abbott Laboratories market value
- $184.1B
- Novo Nordisk market value
- $179B
- Abbott Laboratories P/E
- 39.7
- Novo Nordisk P/E
- 10.3
- Abbott Laboratories revenue
- $44.3BFY to 2025-12-31
- Novo Nordisk revenue
- $45.9BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Abbott Laboratories | Novo Nordisk |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $184.1Bhigher | $179Blower |
| Revenue | $44.3Blower | $45.9Bhigher |
| Earnings | $6.5Blower | $15.2Bhigher |
| Employees | 122,000higher | 68,794lower |
| Total assets | $86.7Bhigher | $80.6Blower |
| Valuation | ||
| P/E | 39.7higher | 10.3lower |
| P/S | 4.2higher | 3.9lower |
| P/B | 3.6 | — |
| Dividend yield | 2.35% | — |
| Profitability | ||
| Operating margin | 18.2%lower | 41.3%higher |
| Balance sheet | ||
| Net assets | $52.1Bhigher | $28.8Blower |
| Total liabilities | $33.9Blower | $51.8Bhigher |
| Total debt | $12.9Blower | $19.4Bhigher |
| Cash on hand | $8.5Bhigher | $3.9Blower |
| Price change | ||
| Today | -1.09%higher | -2.38%lower |
| 1 year | -17.3%lower | -12.5%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- John Overdeck and David Siegel (founders)0.4% / 0.4%
Abbott Laboratories only (14)
- Mason Hawkins4.0%
- Jensen team2.4%
- Diamond Hill team2.2%
- Jeremy Grantham (co-founder)1.9%
- Mairs & Power team0.7%
- Brandon Haley0.5%
- Ken Griffin0.4%
- Paul Tudor Jones0.3%
- Israel Englander0.2%
- Steve Cohen0.2%
- Lew Sanders0.1%
- George Soros0.1%
- Thomas Russo<0.1%
- Howard Gleicher<0.1%
Novo Nordisk only (7)
- Tom Gayner0.8%
- Lee Ainslie0.7%
- Sarah Ketterer0.6%
- Dodge & Cox team0.4%
- Jim Simons (1938–2024)0.2%
- Charles Brandes (founder)0.2%
- Ken Fisher0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Abbott Laboratories / Novo Nordisk). Who owns ABT · Who owns NVO
More on Abbott Laboratories
Further comparisons
Abbott Laboratories against its closest peers
Novo Nordisk against its closest peers
Learn
Questions and answers
Which is bigger, Abbott Laboratories or Novo Nordisk?
By market value, Abbott Laboratories is the larger: $184.1B against $179B for Novo Nordisk. By revenue in its latest fiscal year, Novo Nordisk is the larger: $45.9B against $44.3B for Abbott Laboratories.
Which has the higher P/E ratio?
Abbott Laboratories: 39.7, against 10.3 for Novo Nordisk. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Novo Nordisk: 41.3%, against 18.2% for Abbott Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Novo Nordisk: $19.4B, against $12.9B for Abbott Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Abbott Laboratories and Novo Nordisk?
In their latest 13F filings, John Overdeck and David Siegel (founders) holds both.
Cite this page
Funkfolio, “Abbott Laboratories vs Novo Nordisk”, data as of 17 November 2026. https://funkfolio.com/compare/abt-vs-nvo
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.